In the surveillance and follow-up section it states that continuation of anticoagulation or aspirin was left at the discretion of the treating physician. Later in the paper there is mention of 30-day follow-up of symptomatic recurrent VTE being lowest in the 20mg rivaroxaban group vs the aspirin group (0.2% vs 0.6%). Is there a breakdown of how each of these groups were treated after the study ended? These results might imply a lasting effect of DOAC therapy on reducing recurrent VTE risk (even after treatment was completed), which would be a super interesting idea, OR, if the majority of patients were continued on their original therapy, would simply imply the ongoing benefit of this medication. However, what if a patient was taking high-dose rivaroxaban during the study, then the treating physician subsequently placed the patient on aspirin? Would be great to know more about this, as this might help me better interpret the 30-day follow-up results.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.